Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
OTCPK:TEVJF's Cash to Debt is ranked lower than
80% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. OTCPK:TEVJF: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TEVJF' s 10-Year Cash to Debt Range
Min: 0.07  Med: 0.35 Max: N/A
Current: 0.31
Equity to Asset 0.48
OTCPK:TEVJF's Equity to Asset is ranked lower than
71% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:TEVJF: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TEVJF' s 10-Year Equity to Asset Range
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.48
0.39
0.6
Interest Coverage 13.17
OTCPK:TEVJF's Interest Coverage is ranked lower than
77% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. OTCPK:TEVJF: 13.17 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TEVJF' s 10-Year Interest Coverage Range
Min: 3.6  Med: 8.08 Max: 328.25
Current: 13.17
3.6
328.25
F-Score: 8
Z-Score: 2.18
M-Score: -2.76
WACC vs ROIC
3.05%
9.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.41
OTCPK:TEVJF's Operating margin (%) is ranked higher than
80% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. OTCPK:TEVJF: 18.41 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TEVJF' s 10-Year Operating margin (%) Range
Min: 8.12  Med: 14.85 Max: 26.78
Current: 18.41
8.12
26.78
Net-margin (%) 13.61
OTCPK:TEVJF's Net-margin (%) is ranked higher than
76% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. OTCPK:TEVJF: 13.61 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TEVJF' s 10-Year Net-margin (%) Range
Min: 5.73  Med: 9.39 Max: 21.09
Current: 13.61
5.73
21.09
ROE (%) 11.87
OTCPK:TEVJF's ROE (%) is ranked higher than
65% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. OTCPK:TEVJF: 11.87 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TEVJF' s 10-Year ROE (%) Range
Min: 4.23  Med: 14.44 Max: 27
Current: 11.87
4.23
27
ROA (%) 5.90
OTCPK:TEVJF's ROA (%) is ranked higher than
62% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OTCPK:TEVJF: 5.90 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TEVJF' s 10-Year ROA (%) Range
Min: 2.26  Med: 6.44 Max: 13.11
Current: 5.9
2.26
13.11
ROC (Joel Greenblatt) (%) 42.19
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. OTCPK:TEVJF: 42.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.61  Med: 26.59 Max: 49.79
Current: 42.19
13.61
49.79
Revenue Growth (3Y)(%) 4.80
OTCPK:TEVJF's Revenue Growth (3Y)(%) is ranked lower than
53% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OTCPK:TEVJF: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.8  Med: 15.60 Max: 23.4
Current: 4.8
4.8
23.4
EBITDA Growth (3Y)(%) 10.70
OTCPK:TEVJF's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. OTCPK:TEVJF: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.5  Med: 15.00 Max: 47.2
Current: 10.7
-10.5
47.2
EPS Growth (3Y)(%) 4.80
OTCPK:TEVJF's EPS Growth (3Y)(%) is ranked lower than
51% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OTCPK:TEVJF: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.6  Med: 15.50 Max: 69.8
Current: 4.8
-25.6
69.8
» OTCPK:TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.50
TEVJF's P/E(ttm) is ranked higher than
74% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. TEVJF: 21.50 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53  Med: 20.18 Max: 1072.29
Current: 21.5
10.53
1072.29
Forward P/E 13.19
TEVJF's Forward P/E is ranked higher than
89% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. TEVJF: 13.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.50
TEVJF's PE(NRI) is ranked higher than
74% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. TEVJF: 21.50 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s 10-Year PE(NRI) Range
Min: 10.53  Med: 20.35 Max: 938.25
Current: 21.5
10.53
938.25
P/B 2.59
TEVJF's P/B is ranked higher than
66% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. TEVJF: 2.59 )
Ranked among companies with meaningful P/B only.
TEVJF' s 10-Year P/B Range
Min: 1.37  Med: 2.32 Max: 4.88
Current: 2.59
1.37
4.88
P/S 2.93
TEVJF's P/S is ranked higher than
59% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. TEVJF: 2.93 )
Ranked among companies with meaningful P/S only.
TEVJF' s 10-Year P/S Range
Min: 1.58  Med: 3.19 Max: 5.86
Current: 2.93
1.58
5.86
PFCF 16.85
TEVJF's PFCF is ranked higher than
87% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. TEVJF: 16.85 )
Ranked among companies with meaningful PFCF only.
TEVJF' s 10-Year PFCF Range
Min: 8.45  Med: 17.30 Max: 32.92
Current: 16.85
8.45
32.92
POCF 10.64
TEVJF's POCF is ranked higher than
89% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. TEVJF: 10.64 )
Ranked among companies with meaningful POCF only.
TEVJF' s 10-Year POCF Range
Min: 6.56  Med: 12.94 Max: 23.31
Current: 10.64
6.56
23.31
EV-to-EBIT 17.80
TEVJF's EV-to-EBIT is ranked higher than
68% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. TEVJF: 17.80 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s 10-Year EV-to-EBIT Range
Min: 12  Med: 20.30 Max: 991
Current: 17.8
12
991
PEG 4.57
TEVJF's PEG is ranked lower than
60% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. TEVJF: 4.57 )
Ranked among companies with meaningful PEG only.
TEVJF' s 10-Year PEG Range
Min: 0.38  Med: 1.40 Max: 174.07
Current: 4.57
0.38
174.07
Shiller P/E 24.16
TEVJF's Shiller P/E is ranked higher than
75% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. TEVJF: 24.16 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s 10-Year Shiller P/E Range
Min: 14.08  Med: 33.25 Max: 73.73
Current: 24.16
14.08
73.73
Current Ratio 1.26
TEVJF's Current Ratio is ranked lower than
80% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TEVJF: 1.26 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s 10-Year Current Ratio Range
Min: 1.04  Med: 1.60 Max: 2.95
Current: 1.26
1.04
2.95
Quick Ratio 0.93
TEVJF's Quick Ratio is ranked lower than
79% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TEVJF: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s 10-Year Quick Ratio Range
Min: 0.68  Med: 1.10 Max: 2.19
Current: 0.93
0.68
2.19
Days Inventory 185.78
TEVJF's Days Inventory is ranked lower than
78% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. TEVJF: 185.78 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s 10-Year Days Inventory Range
Min: 131.65  Med: 184.18 Max: 208.14
Current: 185.78
131.65
208.14
Days Sales Outstanding 99.27
TEVJF's Days Sales Outstanding is ranked lower than
69% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. TEVJF: 99.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s 10-Year Days Sales Outstanding Range
Min: 95.91  Med: 118.61 Max: 153.21
Current: 99.27
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
TEVJF's Dividend Yield is ranked higher than
72% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TEVJF: 1.90 )
Ranked among companies with meaningful Dividend Yield only.
TEVJF' s 10-Year Dividend Yield Range
Min: 0.34  Med: 0.95 Max: 3.26
Current: 1.9
0.34
3.26
Dividend Payout 0.42
TEVJF's Dividend Payout is ranked higher than
74% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TEVJF: 0.42 )
Ranked among companies with meaningful Dividend Payout only.
TEVJF' s 10-Year Dividend Payout Range
Min: 0.04  Med: 0.13 Max: 5
Current: 0.42
0.04
5
Dividend growth (3y) 15.30
TEVJF's Dividend growth (3y) is ranked higher than
72% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. TEVJF: 15.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
TEVJF' s 10-Year Dividend growth (3y) Range
Min: -6.7  Med: 27.00 Max: 80.9
Current: 15.3
-6.7
80.9
Yield on cost (5-Year) 5.39
TEVJF's Yield on cost (5-Year) is ranked higher than
94% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. TEVJF: 5.39 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.97  Med: 2.70 Max: 9.25
Current: 5.39
0.97
9.25
Share Buyback Rate 1.30
TEVJF's Share Buyback Rate is ranked higher than
92% of the 463 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. TEVJF: 1.30 )
Ranked among companies with meaningful Share Buyback Rate only.
TEVJF' s 10-Year Share Buyback Rate Range
Min: 2.6  Med: -3.60 Max: -10.9
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.18
TEVJF's Price/Projected FCF is ranked higher than
88% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. TEVJF: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVJF' s 10-Year Price/Projected FCF Range
Min: 0.6  Med: 1.56 Max: 29.17
Current: 1.18
0.6
29.17
Price/DCF (Earnings Based) 1.04
TEVJF's Price/DCF (Earnings Based) is ranked higher than
89% of the 56 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TEVJF: 1.04 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.92
TEVJF's Price/Median PS Value is ranked higher than
85% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TEVJF: 0.92 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.5  Med: 1.07 Max: 1.83
Current: 0.92
0.5
1.83
Earnings Yield (Greenblatt) (%) 5.60
TEVJF's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. TEVJF: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVJF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 4.90 Max: 8.4
Current: 5.6
0.1
8.4
Forward Rate of Return (Yacktman) (%) 9.49
TEVJF's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. TEVJF: 9.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVJF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 7.7  Med: 19.60 Max: 51.2
Current: 9.49
7.7
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEVA.USA, TEVAN.Mexico, TEV.Germany, TEVA.Switzerland, TEVA.Israel,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA Jul 28 2015 
Paul Tudor Jones Buys Stakes in ADP and Visa Jun 19 2015 
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Stanley Druckenmiller's Top 5 New Stocks May 25 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 

More From Other Websites
Teva Pharmaceutical (TEVA) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Former Teva Employee Blames Firing on Helping Feds With Bribery Probe Jul 30 2015
NBIX: Three More Data Readouts Coming in the Second Half of 2015… Jul 30 2015
Are Teva Earnings Enough? Jul 30 2015
Teva's MS drug Copaxone has strong second-quarter sales Jul 30 2015
Teva (TEVA) Beats on 2Q Earnings & Revenues, Raises Outlook - Tale of the Tape Jul 30 2015
RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan Jul 29 2015
More tie-ups in generic drug cos expected Jul 28 2015
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog Jul 28 2015
Pfizer chief executive has 'sufficient courage' to pursue deals Jul 28 2015
There's 'Life After Teva' For Mylan, Says Leerink Jul 28 2015
BMO Ups Teva To Buy; Allergan Deal 'Solidifies Leadership' In Generics Jul 28 2015
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary Jul 28 2015
Will Teva Pharmaceutical (TEVA) Stock Rise Following BMO Capital Upgrade? Jul 28 2015
Has Mylan Labs Been Stichting it to Shareholders? A Lawsuit Says 'Yes!' Jul 28 2015
Top Analyst Upgrades and Downgrades: Baidu, BlackBerry, GM, PayPal, Teva, Yelp and Many More Jul 28 2015
PRESS DIGEST- New York Times business news - July 28 Jul 27 2015
Mylan’s Leverage to Resist Teva Deal Reveals Shift in Rules Jul 27 2015
Allergan sells generic drug unit to Israel's Teva for $40.5 billion Jul 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK